CMS to Release Permanent J-Code for Phesgo™ Injection

Select patients for therapy based on an FDA-approved companion diagnostic test.

Metastatic Breast Cancer
Phesgo™ is indicated for use in combination with docetaxel for the treatment of adult patients with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.

Select patients for therapy based on an FDA-approved companion diagnostic test.

See prescribing information.

Posted on 11/19/2020

Upcoming Events

ACCC Oncology Reimbursement Meeting | Reno

ACCC Oncology Reimbursement Meeting | Reno

In Person November 4, 2026 at 8:00 AM PST255 North Virginia Street, Reno, NV, USAWhitney Peak Hotel Reno, Tapestry Collection by Hilton,
ACCC Oncology Reimbursement Meeting | Providence

ACCC Oncology Reimbursement Meeting | Providence

In Person November 10, 2026 at 8:00 AM EST5 Avenue of the Arts, Providence, RI, USARenaissance Providence Downtown Hotel,